State Of Wyoming Supernus Pharmaceuticals, Inc. Transaction History

State Of Wyoming

$592 Million
Q2 2024

A detailed history of State Of Wyoming transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, State Of Wyoming holds 2,793 shares of SUPN stock, worth $87,085. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,793

Previous 2,484 12.44%

Holding current value

$87,085

Previous $84,000 11.9%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.99 - $33.85 $8,030 - $10,459	309 Added 12.44%	2,793 $74,000
Q1 2024 May 13, 2024	SELL	$27.11 - $35.17 $4,364 - $5,662	-161 Reduced 6.09%	2,484 $84,000
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $17,994 - $23,506	-792 Reduced 23.04%	2,645 $76,000
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $69,228 - $82,637	-2,511 Reduced 42.22%	3,437 $94,000
Q2 2023 Aug 14, 2023	BUY	$29.91 - $38.73 $658 - $852	22 Added 0.37%	5,948 $178,000
Q1 2023 May 12, 2023	SELL	$34.93 - $42.03 $13,797 - $16,601	-395 Reduced 6.25%	5,926 $214,000
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $79,870 - $97,313	2,569 Added 68.47%	6,321 $225,000
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $45,344 - $55,770	-1,575 Reduced 29.57%	3,752 $127,000
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $48,912 - $66,136	1,931 Added 56.86%	5,327 $154,000
Q1 2022 May 13, 2022	BUY	$28.51 - $32.9 $35,951 - $41,486	1,261 Added 59.06%	3,396 $110,000
Q4 2021 Feb 11, 2022	SELL	$26.37 - $34.22 $1,661 - $2,155	-63 Reduced 2.87%	2,135 $62,000
Q3 2021 Feb 11, 2022	BUY	$23.54 - $31.39 $8,615 - $11,488	366 Added 19.98%	2,198 $59,000
Q2 2021 Feb 11, 2022	BUY	$26.72 - $33.19 $48,951 - $60,804	1,832 New	1,832 $56,000

Others Institutions Holding SUPN

# of Institutions

255

Shares Held

59.2M

Call Options Held

47.9K

Put Options Held

13.1K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.67B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wyoming with notifications on news.

Account